Kincell Bio partners RegCell to advance Treg therapy trials

A new collaboration between U.S. cell-therapy manufacturer Kincell Bio and biotechnology innovator RegCell aims to accelerate the clinical development of a next-generation immune-tolerance therapy designed to treat autoimmune diseases.

Under the agreement, Kincell Bio will provide chemistry, manufacturing and controls (CMC) development and Good Manufacturing Practice (GMP) clinical manufacturing support for RegCell’s lead regulatory T-cell (Treg) program. The partnership includes process transfer, analytical development, manufacturing optimization and production of clinical-grade material to support Investigational New Drug (IND)-enabling studies and early-stage clinical trials.

The companies said the collaboration is intended to shorten development timelines while ensuring reliable clinical supply — a critical hurdle for emerging cell-therapy programs. By leveraging Kincell Bio’s manufacturing expertise early, RegCell hopes to build a commercially viable production process alongside clinical development rather than after proof-of-concept studies.

RegCell’s platform focuses on restoring immune tolerance by converting disease-driving CD4+ T cells into stable, antigen-matched regulatory T cells. The technology reproduces key epigenetic features responsible for Treg identity and durability, potentially allowing long-lasting therapeutic effects without continuous treatment.

The company was founded by immunologist Shimon Sakaguchi of Osaka University and professor emeritus at Kyoto University, whose work on immune tolerance and regulatory T cells earned a share of the 2025 Nobel Prize in Physiology or Medicine. His research established Tregs as a central mechanism preventing autoimmune reactions, laying the groundwork for therapeutic applications.

Unlike many advanced cell therapies, RegCell’s approach does not rely on gene editing or viral DNA vectors. The company says eliminating these components reduces manufacturing complexity, improves scalability and could enable automated production — potentially even point-of-care treatment in the future.

Executives from both organizations emphasized the strategic importance of integrating manufacturing expertise early in development. RegCell noted that access to specialized T-cell production capabilities will allow it to concentrate on clinical strategy and therapeutic validation, while Kincell Bio highlighted its role in translating innovative immunology into real-world therapies.

The partnership reflects a broader trend in the cell-therapy industry, where developers increasingly collaborate with specialized contract manufacturers to overcome production bottlenecks that can delay clinical progress. If successful, the collaboration could accelerate a new category of immune-tolerance therapies aimed at treating autoimmune disorders by retraining — rather than suppressing — the immune system.